Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses

Journal of Virology

Volumn 86, Issue 11, 2012, Pages 6334-6340

  Krause, Jens C ^a   Tsibane, Tshidi ^c   Tumpey, Terrence M ^d   Huffman, Chelsey J ^a   Albrecht, Randy ^c   Blum, David L ^a   Ramos, Irene ^c   Fernandez Sesma, Ana ^c   Edwards, Kathryn M ^a   García Sastre, Adolfo ^c   Basler, Christopher F ^c   Crowe, James E ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2G1; MONOCLONAL ANTIBODY 8F8; MONOCLONAL ANTIBODY 8M2; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SCREENING; ARTICLE; ASIAN INFLUENZA; B LYMPHOCYTE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; EMBRYO; EPITOPE MAPPING; FEMALE; GENE; HEMAGGLUTINATION INHIBITION TEST; HONG KONG INFLUENZA; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNIZATION; IN VIVO STUDY; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H3N2; MOLECULAR CLONING; MOUSE; NONHUMAN; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROVOCATION TEST; RECEPTOR BINDING; SEQUENCE ANALYSIS; VH1 69 GERM LINE GENE; VIRUS EXAMINATION; VIRUS INHIBITION; VIRUS MUTANT; ADULT; ANIMAL; BAGG ALBINO MOUSE; CHICK EMBRYO; DISEASE MODEL; DNA SEQUENCE; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; INFLUENZA; ISOLATION AND PURIFICATION; MIDDLE AGED; MISSENSE MUTATION; MOLECULAR GENETICS; MORTALITY; ORTHOMYXOVIRUS INFECTION; SURVIVAL; VIROLOGY;

INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE; SUIDAE;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CHICK EMBRYO; DISEASE MODELS, ANIMAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H2N2 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; ORTHOMYXOVIRIDAE INFECTIONS; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS;

EID: 84863568230     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07158-11     Document Type: Article

References (55)

1. Bernstein DI, et al. 2008. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis. 197:667-675.
2. Brochet X, Lefranc MP, Giudicelli V. 2008. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36:W503-W508.
3. Caton A, Brownlee G, Yewdell J, Gerhard W. 1982. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31:417-427.
4. Chen BJ, Leser GP, Morita E, Lamb RA. 2007. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J. Virol. 81:7111-7123.
5. Choppin PW, Tamm I. 1960. Studies of two kinds of virus particles which comprise influenza A2 virus strains. II. Reactivity with virus inhibitors in normal sera. J. Exp. Med. 112:921-944.
6. Connor RJ, Kawaoka Y, Webster RG, Paulson JC. 1994. Receptor specificity in human, avian, and equineH2andH3influenza virus isolates. Virology 205:17-23.
7. Corti D, et al. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120:1663-1673.
8. Dawood FS, et al. 2009. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360:2605-2615.
9. Ekiert DC, et al. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324:246-251.
10. Hehme N, Engelmann H, Kunzel W, Neumeier E, Sanger R. 2002. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med. Microbiol. Immunol. 191:203-208.
11. Hensley SE, et al. 2009. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 326:734-736.
12. Hilleman MR. 2002. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 20:3068-3087.
13. Kaverin NV, et al. 2000. Cross-protection and reassortment studies with avian H2 influenza viruses. Arch. Virol. 145:1059-1066.
14. Knossow M, Skehel JJ. 2006. Variation and infectivity neutralization in influenza. Immunology 119:1-7.
15. Krause JC, et al. 2011. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J. Virol. 85:10905-10908.
16. Krause JC, et al. 2011. Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence. J. Immunol. 187:3704-3711.
17. Larkin MA, et al. 2007. Clustal W and Clustal X version 2.0. Bioinformatics 23:2947-2948.
18. Ma W, et al. 2007. Identification of H2N3 influenza A viruses from swine in the United States. Proc. Natl. Acad. Sci. U. S. A. 104:20949-20954.
19. Matrosovich M, et al. 2000. Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. J. Virol. 74:8502-8512.
20. Nabel GJ, Wei CJ, Ledgerwood JE. 2011. Vaccinate for the next H2N2 pandemic now. Nature 471:157-158.
21. Nagieva FG, et al. 1989. Preparation and properties of monoclonal antibodies to influenza virus A/Krasnodar/101/59 (H2N2). Vopr. Virusol. 34: 543-547.
22. National Research Council. 1996. Guide for the care and use of laboratory animals. Office of Laboratory Animal Welfare, National Institutes of Health, Bethesda, MD.
23. Ohshima N, et al. 2011. Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5. J. Virol. 85:11048-11057.
24. Okada J, et al. 2011. Localization of epitopes recognized by monoclonal antibodies that neutralized the H3N2 influenza viruses in man. J. Gen. Virol. 92:326-335.
25. Okada J, et al. 2010. Monoclonal antibodies in man that neutralized H3N2 influenza viruses were classified into three groups with distinct strain specificity: 1968-1973, 1977-1993 and 1997-2003. Virology 397: 322-330.
26. Okuno Y, Isegawa Y, Sasao F, Ueda S. 1993. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67:2552-2558.
27. Pappas C, et al. 2010. Receptor specificity and transmission of H2N2 subtype viruses isolated from the pandemic of 1957. PLoS One 5:e11158.
28. Pyhala R. 1985. Antibody status to influenza A/Singapore/1/57(H2N2) in Finland during a period of outbreaks caused by H3N2 and H1N1 subtype viruses. J. Hyg. (Lond.) 95:437-445.
29. Schäfer JR, et al. 1993. Origin of the pandemic 1957 H2 influenza A virus and the persistence of its possible progenitors in the avian reservoir. Virology 194:781-788.
30. Shibuya T, et al. 2008. Identification of a human monoclonal Fab with neutralizing activity against H3N2 influenza A strain from a newly constructed human Fab library. Microbiol. Immunol. 52:162-170.
31. Squires B, et al. 2008. BioHealthBase: informatics support in the elucidation of influenza virus host pathogen interactions and virulence. Nucleic Acids Res. 36:D497-D503.
32. Stevens J, et al. 2004. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 303:1866-1870.
33. Stöhr K. 2010. Vaccinate before the next pandemic? Nature 465:161.
34. Sui J, et al. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16:265-273.
35. Taubenberger JK, Morens DM. 2010. Influenza: the once and future pandemic. Public Health Rep. 125(Suppl 3):16-26.
36. Tsuchiya E, et al. 2001. Antigenic structure of the haemagglutinin of human influenza A/H2N2 virus. J. Gen. Virol. 82:2475-2484.
37. Underwood PA. 1984. An antigenic map of the haemagglutinin of the influenza Hong Kong subtype (H3N2), constructed using mouse monoclonal antibodies. Mol. Immunol. 21:663-671.
38. Underwood PA. 1982. Mapping of antigenic changes in the haemagglutinin of Hong Kong influenza (H3N2) strains using a large panel of monoclonal antibodies. J. Gen. Virol. 62(Pt 1):153-169.
39. Viswanathan K, et al. 2010. Determinants of glycan receptor specificity of H2N2 influenza A virus hemagglutinin. PLoS One 5:e13768.
40. Walls HH, Harmon MW, Slagle JJ, Stocksdale C, Kendal AP. 1986. Characterization and evaluation of monoclonal antibodies developed for typing influenzaAand influenza B viruses. J. Clin. Microbiol. 23:240-245.
41. Webster RG. 1997. Predictions for future human influenza pandemics. J. Infect. Dis. 176(Suppl 1):S14-S19.
42. Webster RG, Laver WG. 1980. Determination of the number of nonoverlapping antigenic areas on Hong Kong (H3N2) influenza virus hemagglutinin with monoclonal antibodies and the selection of variants with potential epidemiological significance. Virology 104:139-148.
43. Webster RG, et al. 1980. The mechanism of antigenic drift in influenza viruses: analysis of Hong Kong (H3N2) variants with monoclonal antibodies to the hemagglutinin molecule. Ann. N. Y. Acad. Sci. 354:142-161.
44. Whittle JR, et al. 2011. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc. Natl. Acad. Sci. U. S. A. 108:14216-14221.
45. World Health Organization Collaborating Centers for Reference and Research on Influenza. 1982. Concepts and procedures for laboratorybased influenza surveillance. Centers for Disease Control, Atlanta, GA.
46. Wrammert J, et al. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208:181-193.
47. Wrammert J, et al. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453:667-671.
48. Wright PF, Neumann G, Kawaoka Y. 2007. Fields virology, 5th ed, p 1699. In Knipe DM, et al (ed), Lippincott Williams & Wilkins, Philadelphia, PA.
49. Xu R, McBride R, Paulson JC, Basler CF, Wilson IA. 2010. Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J. Virol. 84:1715-1721.
50. Yamada A, Brown LE, Webster RG. 1984. Characterization of H2 influenza virus hemagglutinin with monoclonal antibodies: influence of receptor specificity. Virology 138:276-286.
51. Yamashita A, et al. 2010. Highly conserved sequences for human neutralization epitope on hemagglutinin of influenza A viruses H3N2, H1N1 and H5N1: implication for human monoclonal antibody recognition. Biochem. Biophys. Res. Commun. 393:614-618.
52. Yewdell JW, Webster RG, Gerhard WU. 1979. Antigenic variation in three distinct determinants of an influenza type A haemagglutinin molecule. Nature 279:246-248.
53. Yoshida R, et al. 2009. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog. 5:e1000350.
54. Yu X, McGraw PA, House FS, Crowe JE, Jr. 2008. An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies. J. Immunol. Methods 336:142-151.
55. Yu X, et al. 2008. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 455:532-536.